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Abstract: A series of new benzophenone and diphenylmethane halophenol derivatives were 
prepared. Their structures were established based on 
1H NMR, 
13C NMR and HRMS data. 
All prepared compounds were screened for their in vitro protein tyrosine kinase (PTK) 
inhibitory  activities.  The  effects  of  modification  of  the  linker,  functional  groups  and 
substituted positions at the phenyl ring on PTK inhibitory activity were investigated. Twelve 
halophenols showed significant PTK inhibitory activity. Among them, compounds 6c, 6d, 
7d, 9d, 10d, 11d and 13d exhibited stronger activities than that of genistein, the positive 
reference  compound.  The  results  gave  a  relatively  full  and  definite  description  of  the 
structure–activity relationship and provided a foundation for further design and structure 
optimization of the halophenols. 
Keywords:  protein  tyrosine  kinase;  halophenol;  structure–activity  relationship; 
benzophenone; diphenylmethane 
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1. Introduction 
Protein  tyrosine  kinases  (PTKs),  which  are  members  of  a  large  family  of  oncoproteins  and 
proto-oncoproteins, play a major role in mitogenic signal transduction, and are involved in the control 
of cell proliferation, differentiation and transformation. Continuing activation of PTK is associated 
with  proliferative  disorders  such  as  cancer;  hence,  PTK  inhibitors  have  been  developed  as 
molecular-targeting cancer therapeutic agents. The discovery and development of PTK inhibitors as 
new cancer therapeutic agents have now attracted much attention [1–9]. To date, many PTK inhibitors 
with  potent  activities  have  already  passed  or  are  currently  in  clinical  trials  to  investigate  their 
applicability as anti-cancer drugs [10]. 
Various structural halophenols isolated from biologically active natural products such as various 
marine algae, ascidians and sponges present a wide spectrum of bioactivities including protein tyrosine 
phosphatase (PTP1B) inhibitory [11], antioxidative [12,13], antithrombotic [14], antimicrobial [15,16], 
anti-inflammatory [17], enzyme inhibitory [18], cytotoxic [19], and appetite suppressant
 [20], PTK 
inhibitory  activities  [21].  However,  to  the  best  of  our  knowledge,  very  little  is  known  about  the 
inhibitory  activity  of  benzophenone  and  diphenylmethane  halophenols  against  PTK,  and  their 
corresponding structure–activity relationships (SARs) have been rarely reported, despite the fact that 
several  natural diphenylmethane  bromophenols  isolated from the  brown alga Leathesia nana  have 
been reported to show moderate inhibitory activity against PTK with over-expression of c-kit [21], 
which  reveals  that  diphenylmethane  halophenols  may  possess  potential  significant  PTK 
inhibitory activity. 
We  therefore  designed  and  synthesized  a  series  of  new  diphenylmethane  and  benzophenone 
halophenol derivatives by modification of the linker (illustrated in Table 1), functional groups, and 
substituted positions at the phenyl ring to find novel structural halophenol derivatives with strong PTK 
inhibitory activity, and tried to establish the SAR on the basis of this new compound library. In our 
previous study [22], a series of bromo- and chloro- substituted halophenols were reported for their 
significant in vitro antioxidative and cytoprotective activities. However, the PTK inhibitory activity 
has not been evaluated. In the continued efforts towards discovering potent PTK inhibitors, a series   
of new fluoro- and iodo- functionalized benzophenone and diphenylmethane halophenols derivatives 
were also prepared and screened for their in vitro PTK inhibitory activity with genistein as positive 
control [23,24], in accordance with the fact that inclusion of F or I atoms in a compound may have 
profound effects on drug disposition [25–30]. The results provide some clear and useful information 
about recognition of the SAR.   
2. Results and Discussion 
2.1. Chemistry 
A series of new benzophenone and diphenylmethane halophenol derivatives with several groups 
substituted at different positions on the phenyl ring were synthesized to determine how the substituents 
affect the PTK inhibitory activity. Halophenol compounds 5c-13c and 5d-13d were prepared in our 
previous  study  [22].  In  the  present  study,  12  fluoro-  and  four  iodo-  functionalized  halophenol   
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derivatives (1a-4d) were also prepared (Scheme 1), including 11 new compounds 1b, 1c, 1d, 2b, 2c, 
2d, 3b, 3d, 4b, 4c and 4d. 
Scheme  1.  Synthesis  of  benzophenone  and  diphenylmethane  halophenol  derivatives. 
Reagents and conditions: (a) AlCl3/CH2Cl2, rt, 4 h; (b) LiAlH4/AlCl3/ether, 40 °C, refluxed 
for 2 h; (c) BBr3/CH2Cl2(1/9, v/v) was added to the solution at −78 °C, warmed to room 













































2.2. In vitro PTK Inhibitory Activity 
The in vitro PTK inhibitory activity of the prepared compounds listed in Table 1 was tested by 
ELISA  with  genistein  as  a  positive  reference  compound.  As  shown  in  Table  1,  12  halophenols 
exhibited  strong  activities,  which  in  some  cases,  were  identical  to,  or  even  higher  than,  that  of 
genistein  in the same  model. Among these, seven compounds, 6c, 6d, 7d, 9d, 10d, 11d and 13d, 
showed the strongest activities with IC50 values of 2.97–12.9 μM, which were stronger than that of 
genistein with an IC50 value of 13.6 μM. Compound 8d with an IC50 value of 14.8 μM exhibited 
identical activity to genistein. Compounds 8c, 9c and 11c showed lower activities with IC50 values of 
17.7, 17.8 and 16.0 μM, respectively. Compound 10c exhibited weak activity with an IC50 of 41.6 μM. 
Table 1. Structures and in vitro protein tyrosine kinase (PTK) inhibitory activities of the 
prepared halophenols. PTK activity was determined by the ELISA method with genistein 













Substituted group  IC50 
a 
(μM)  Linker  R1  R2  R3  R4  R5  R6  R7  R8  R9 
1c *  C=O  F  H  H  H  H  H  H  OH  OH  >50 
1d *  CH2  F  H  H  H  H  H  H  OH  OH  >50 
2c *  C=O  H  F  H  H  H  H  H  OH  OH  >50 Int. J. Mol. Sci. 2011, 12  6107 
 
Table 1. Cont. 
Compd. 
 
Substituted group  IC50 
a 
(μM)  Linker  R1  R2  R3  R4  R5  R6  R7  R8  R9 
2d *  CH2  H  F  H  H  H  H  H  OH  OH  >50 
3c  C=O  H  H  F  H  H  H  H  OH  OH  >50 
3d *  CH2  H  H  F  H  H  H  H  OH  OH  >50 
4c *  C=O  I  H  H  H  H  H  H  OH  OH  >50 
4d *  CH2  I  H  H  H  H  H  H  OH  OH  >50 
5c  C=O  Br  OH  OH  OH  Br  H  H  OH  OH  >50 
5d  CH2  Br  OH  OH  OH  Br  H  H  OH  OH  >50 
6c  C=O  Cl  OH  OH  OH  Cl  H  H  OH  OH  2.97 
6d  CH2  Cl  OH  OH  OH  Cl  H  H  OH  OH  3.96 
7c  C=O  H  Br  OH  H  H  Br  H  OH  OH  >50 
7d  CH2  H  Br  OH  H  H  Br  H  OH  OH  6.34 
8c  C=O  Cl  H  H  H  H  H  H  OH  OH  17.7 
8d  CH2  Cl  H  H  H  H  H  H  OH  OH  14.8 
9c  C=O  H  Cl  H  H  H  H  H  OH  OH  17.8 
9d  CH2  H  Cl  H  H  H  H  H  OH  OH  12.9 
10c  C=O  H  H  Cl  H  H  H  H  OH  OH  41.6 
10d  CH2  H  H  Cl  H  H  H  H  OH  OH  6.97 
11c  C=O  H  H  H  H  H  Br  H  OH  OH  16.0 
11d  CH2  H  H  H  H  H  Br  H  OH  OH  6.26 
12c  C=O  H  H  H  H  H  Br  Br  OH  OH  >50 
12d  CH2  H  H  H  H  H  Br  Br  OH  OH  >50 
13c  C=O  OH  H  H  Br  H  Br  H  OH   OH  >50 




                 
13.6 
* New compound; 
a The IC50 values were determined in triplicate. 
2.3. SAR Analysis 
Diphenylmethane halophenols 7d, 8d, 9d, 10d, 11d and 13d displayed higher activities with IC50 
values  of  6.34,  14.8,  12.9,  6.97,  6.26  and  5.05  μM  than  those  of  corresponding  benzophenone 
halophenols 7c, 8c, 9c, 10c, 11c and 13c. Bromophenols 7c and 13c, which are isomers, showed no 
activity. Isomers of chlorophenols 8c, 9c, 10c and bromophenol 11c exhibited moderate activity with 
IC50 values of 17.7, 17.8, 41.6 and 16.0 μM, respectively. Replacement of the methylene group by a 
carbonyl  group,  except  6c  which  showed  similar  activity  to  6d,  led  to  an obvious  decrease,  even 
complete  disappearance  of  the  activity,  which  suggested  that  the  methylene  group  may  greatly 
contribute to the PTK inhibitory activity. 
Meanwhile, substitution of the hydroxyl groups by methoxyl groups resulted in the disappearance 
of activity, and indeed, none of the compounds with methoxyl groups on the phenyl ring showed any 
activity with IC50 value higher than 50 μM. This indicated that the methoxyl group exerted a great 
negative  effect  on  the  PTK  inhibitory  activity,  and  also  illustrated that the  hydroxyl  groups  were   
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essential. It is implied that these active halophenols as hydrogen donors could have key interactions 
with PTK. 
By  comparing  the  activities  of  the  halogen-substituted  compounds  5c,  6c,  5d  and  6d,  which 
possessed five hydroxyls and two halogen atoms at the same positions, we found that the chlorophenol 
compounds 6c and 6d exhibited the strongest activities with IC50 values of 2.97 μM and 3.96 μM, 
respectively.  However,  the  bromophenols  5c  and  5d  showed  no  activity.  Moreover,  for  all  of  the 
fluoro- and iodo- functionalized halophenols, no activity was observed. Hence, the halogen atoms on 
the phenyl ring contributed to the activity in the order of Cl > Br > F (or I), which suggested that the 
chloro atom  may play a pivotal role  between the  interaction of active  halophenols and PTK. The 
results also showed that an increased number of hydroxyl groups and chloro atoms may be beneficial 
to the activity.   
Compounds 8c and 9c with a chloro atom at the ortho- and meta- position of the carbonyl group 
exhibited moderate activities, with IC50 values of 17.7 μM and 17.8 μM, respectively. Compound 10c 
with a chloro atom at the para-position of the carbonyl group showed weak activity, with an IC50 value 
of 41.6 μM. Compounds 10d and 9d, with a chloro atom at the para- and meta- position of the methene 
group, showed high activities with IC50 values of 6.97 μM and 12.9 μM, respectively. Compound 8d 
with a chloro atom at the ortho-position of the methene group exhibited identical activity with an IC50 
value of 14.8 μM, compared to that of the positive control compound (IC50 = 13.6 μM). To the isomers 
of  these  chlorophenols,  the  chloro  atom  substituted  at  different  position  on  the  phenyl  ring  had 
significant effects on the activity. In addition, the same substituted position of the chloro atom on the 
phenyl  ring  had  an  entirely  different  effect  on  the  activity  of  benzophenone  and  diphenylmethane 
halophenols. The results indicated that the linker and halogen had a combined influence on the activity.   
The activities of compounds 12c and 12d were not enhanced by the increased number of halogen 
atoms.  The  bromophenols  11c  and  11d  substituted  by  one  bromo  atom  obviously  showed  better 
activities than those of bromophenols 12c and 12d with two bromo atoms at the same phenyl ring.   
3. Experimental Section 
3.1. General 
Melting points were taken on a micromelting point apparatus, which were uncorrected. 
1H and 
13C 
NMR spectra were recorded with a Bruker-AV 400 spectrometer at 400 and 100 MHz respectively, in 
CDCl3,  DMSO-d6  or  CD3OD  with  TMS  as  reference.  Chemical  shifts  (δ  values)  and  coupling 
constants (J values) were given in ppm and Hz, respectively. ESI mass spectra were obtained on an 
API QTRAP 3200 MS spectrometer, and HRMS were recorded on a Bruker Daltonics Apex IV 70e 
FTICR-MS (Varian 7.0T). 
Ether was distilled from sodium benzophenone ketyl. Dichloromethane was distilled from calcium 
hydride. Other reagents and solvents were commercially available unless otherwise indicated. Int. J. Mol. Sci. 2011, 12  6109 
 
3.2. Typical Procedures for the Preparation of Halophenol Derivatives   
The  general  procedures  for  compounds  5c–13c,  and  5d–13d  have  been  reported  in  our  earlier   
study [22]. A series of new fluoro- and iodo- functionalized compounds were prepared according to 
the following general procedures. 
3.2.1. Preparation of compounds 1a–4a 
2-fluoro-3’,4’-dimethoxyl  benzophenone  (1a):  2-Fluorobenzoyl  chloride  (10  mL,  82.2  mmol)  was 
added at 0 °C to a solution that contained 1,2-dimethoxybenzene (10 mL, 78.5 mmol) in dried CH2Cl2 
(60 mL). Anhydrous AlCl3 (11.1 g, 83.2 mmol) was added by portion wise. The mixture was allowed 
to warm to room temperature and stirred for 4 h, then ice-water (100 mL) was added to the mixture. 
The organic phase was separated, washed with water (50 mL) and dried over anhydrous Na2SO4. The 
solvent  was  evaporated  under  reduced  pressure,  and  the  crude  product  was  recrystallized  from 
methanol to give compound 1a as a white powder in 73% yield. m.p. 77–79 °C; 
1H NMR (CDCl3) δ: 
7.58  (d,  1H,  Ph-6-H),  7.15–7.55  (m,  5H,  PhH),  6.90  (d,  1H,  Ph-5'-H),  3.97  (s,  3H,  OCH3),   
3.96 (s, 3H, OCH3); 
13C NMR (CDCl3) δ: 192.0, 161.0, 158.5, 153.8, 149.1, 132.5, 132.4, 130.5, 130.4, 
130.3, 127.5, 127.4, 125.9, 124.2, 124.1, 116.3, 116.1, 111.0, 109.9, 56.1, 56.0; MS (ESI) m/z: 261.0 
([M + H]
+, 100). 
Compounds 2a–4a were prepared in the similar manner as described for 1a. 
3-fluoro-3',4'-dimethoxyl benzophenone (2a): White powder, Yield 80%, mp 103–105 °C; 
1H NMR 
(CDCl3) δ: 7.46–7.56 (m, 4H, Ph-2,4,5,6-H), 7.39 (dd, J = 2.0, 8.4 Hz, 1H, Ph-6'-H), 7.26–7.30 (m, 1H, 
Ph-2’-H), 6.93 (d, J = 8.4 Hz, 1H, Ph-5’-H), 3.96 (s, 3H, OCH3), 3.98 (s, 3H, OCH3); 
13C NMR 
(CDCl3) δ: 194.1, 163.6, 161.2, 153.3, 149.2, 140.4, 140.3, 129.9, 129.8, 129.6, 125.6, 125.4, 118.9, 
118.7, 116.6, 116.4, 112.0, 109.8, 56.1, 56.1; MS (ESI) m/z: 261.0 ([M + H]
+, 100). 
4-fluoro-3',4'-dimethoxyl benzophenone (3a): White powder, Yield 86%, mp 101–103 °C; 
1H NMR 
(CDCl3)  δ:  7.80–7.84  (m,  2H,  Ph-2,6-H),  7.48  (d,  J  =  2.0  Hz,  1H,  Ph-2'-H),  7.37  (dd,  J  =  2.0,   
8.4 Hz, 1H, Ph-6'-H), 7.15–7.19 (m, 2H, Ph-3,5-H), 6.93 (d, J = 8.4 Hz, 1H, Ph-5'-H), 3.98 (s, 3H, 
OCH3), 3.96 (s, 3H, OCH3); 
13C NMR (CDCl3) δ: 194.2, 166.3, 163.8, 153.1, 149.1, 134.4, 132.3, 
132.2, 130.1, 125.2, 115.4, 115.2, 112.1, 109.8, 56.1, 56.0; MS (ESI) m/z: 261.0 ([M + H]
+, 100). 
2-iodo-3',4'-dimethoxyl  benzophenone  (4a):  White  powder,  Yield  85%,  mp  143–145  °C; 
1H  NMR 
(CDCl3) δ: 7.93 (d, J = 8.0 Hz, 1H, Ph-3-H), 7.60 (d, J = 2.0 Hz, 1H, Ph-6-H), 7.45 (m, 1H, Ph-5-H), 
7.31 (dd, J = 2.0, 8.0 Hz, 1H, Ph-4-H), 7.16–7.21 (m, 2H, Ph-2',6'-H), 6.86 (d, J = 8.4 Hz, 1H, Ph-5
’-H), 
3.96 (s, 3H, OCH3), 3.95 (s, 3H, OCH3); 
13C NMR (CDCl3) δ: 196.1, 154.0, 149.4, 144.7, 139.5, 130.9, 
128.6, 128.2, 127.7, 126.8, 111.1, 109.9, 92.4, 56.2, 56.1; MS (ESI) m/z: 369.0 ([M + H]
+, 100). 
3.2.2. The Preparation of Compounds 1b–4b 
2-fluoro-3',4'-dimethoxyl diphenylmethane (1b): Anhydrous AlCl3 (2.00 g, 15.0 mmol) and LiAlH4 
(1.00 g, 26.4 mmol) were slowly added to dried ether (50 mL). After stirring for 5 min, compound 1a 
(2.00 g, 7.69 mmol) was dissolved in dried ether (10 mL) and dropwisely added to the solution. The 
mixture was warmed to 40 °C , refluxed for 2 h, then cooled and quenched with 50 mL 18% aqueous Int. J. Mol. Sci. 2011, 12  6110 
 
HCl.  The  organic  phase  was  separated.  The  water  layer  was  extracted  twice  with  ethyl  acetate   
(2 × 30 mL). The combined organics were washed to neutral with water, dried over anhydrous Na2SO4, 
and  then  concentrated  via  rotary  evaporation.  The  crude  product  was  purified  by  silica  gel 
chromatography with ethyl acetate-petroleum ether (1/9) as eluent to afford compound 1b. The product 
was  recrystallized  from  methanol  to  give  a  white  powder  in  40%  yield.  mp  51–52  °C; 
1H  NMR 
(CDCl3) δ: 7.04–7.24 (m, 4H, Ph-3,4,5,6-H), 6.77–6.84 (m, 3H, Ph-2',5',6'-H), 3.97 (s, 2H, CH2), 3.88 
(s, 3H, OCH3), 3.87 (s, 3H, OCH3); 
13C NMR (CDCl3) δ: 162.1, 159.7, 149.0, 147.5, 132.4, 130.9, 
130.8, 128.4, 128.3, 127.9, 127.8, 124.1, 124.0, 120.8, 115.4, 115.2, 112.1, 111.2, 55.9, 55.8, 34.4; MS 
(ESI) m/z: 247.0 ([M + H]
+, 100). 
Compounds 2b-4b were prepared in the similar manner as described for 1b. 
3-fluoro-3',4'-dimethoxyl  diphenylmethane  (2b):  Yellow  liquid,  Yield  62%; 
1H  NMR  (CDCl3)   
δ: 7.26–7.30 (m, 1H, Ph-5-H), 7.01 (d, 1H, J = 7.2 Hz, Ph-6-H), 6.89–6.94 (m, 2H, Ph-2, 4-H), 6.85   
(d, 1H, J = 8.0 Hz, Ph-5'-H), 6.72–6.77 (m, 2H, Ph-2',6'-H), 3.95 (s, 2H, CH2), 3.89 (s, 3H, OCH3), 
3.87 (s, 3H, OCH3); 
13C NMR (CDCl3) δ: 164.2, 161.8, 149.0, 147.6, 144.1,  144.0, 132.8, 129.9,   
129.8, 124.4, 121.0, 115.8, 115.5, 113.1, 112.9, 112.2, 111.3, 55.9, 55.8, 41.2; MS (ESI) m/z: 247.0 
([M + H]
+, 100). 
4-fluoro-3',4'-dimethoxyl  diphenylmethane  (3b):  Yellow  liquid,  Yield  40%; 
1H  NMR  (CDCl3)   
δ: 7.15–7.18 (m, 2H, Ph-2,6,-H), 6.98–7.02 (m, 2H, Ph-3,5-H), 6.84 (d, 1H, J = 8.0 Hz, Ph-5'-H), 
6.71–6.75 (m, 2H, Ph-2’,6’-H), 3.93 (s, 2H, CH2), 3.89 (s, 3H, OCH3), 3.86 (s, 3H, OCH3); 
13C NMR 
(CDCl3) δ: 162.6, 160.2, 149.0, 147.5, 137.1, 137.0, 133.5, 130.2, 130.1, 120.8, 115.3, 115.1, 112.1, 
111.3, 55.9, 55.8, 40.6; MS (ESI) m/z: 247.0 ([M + H]
+, 100). 
2-iodo-3',4'-dimethoxyl  diphenylmethane  (4b):  White  powder,  Yield  23%,  mp  48–49  °C;   
1H NMR (CDCl3) δ: 7.90 (dd, J = 1.2, 8.0 Hz, 1H, Ph-3-H), 7.27–7.31 (m, 1H, Ph-5-H), 7.13 (dd,   
J = 1.2, 7.6 Hz, 1H, Ph-6-H), 6.91–6.96 (m, 1H, Ph-4-H), 6.82 (d, J = 8.0 Hz, 1H, Ph-5'-H), 6.72–6.74 
(m, 2H, Ph-2',6'-H), 4.06 (s, 2H, CH2), 3.89 (s, 3H, OCH3), 3.86 (s, 3H, OCH3); 
13C NMR (CDCl3)   
δ: 149.0, 147.6, 143.9, 139.5, 132.1, 130.2, 128.4, 128.0, 121.1, 112.4, 112.2, 101.2, 55.9, 55.8, 46.2; 
MS (ESI) m/z: 355.0 ([M + H]
+, 100). 
3.2.3. The Preparation of Compounds 1c–4c 
2-fluoro-3',4'-dihydroxyl benzophenone (1c): Ten milliliters BBr3 solution (BBr3/CH2Cl2, v/v, 1/9) 
was dropwisely added to a cooled (–78 °C) solution of compound 1a (500 mg, 1.92 mmol) in dried 
CH2Cl2 (20  mL). The  mixture was warmed to room temperature, stirred for 2 h,  and poured into 
ice-water (50 mL). The organic phase was separated. The water layer was extracted twice with ethyl 
acetate (2 × 20 mL). The combined organics were washed with 20 mL water, dried over anhydrous 
Na2SO4  and  concentrated  via  rotary  evaporation.  The  crude  product  was  purified  by  silica  gel 
chromatography  with  ethyl  acetate-petroleum  ether  (1/4,  containing  1  mL  acetic  acid  in  100  mL 
elution solvent) as eluent to afford compound 1c as a white powder in 53% yield. mp 149–150 °C;   
1H NMR (DMSO-d6) δ: 7.58–7.63 (m, 1H, Ph-6-H), 7.46–7.50 (m, 1H, Ph-4-H), 7.32–7.38 (m, 2H, 
Ph-3,5-H), 7.26 (d, 1H, J = 1.6 Hz, Ph-2’-H), 7.12 (dd, 1H, J = 1.2, 8.4 Hz, Ph-6'-H), 6.87 (d, 1H,   
J = 8.4 Hz, Ph-5'-H), 3.40 (br, 2H, Ph-OH); 
13C NMR (DMSO-d6) δ: 191.5, 160.4, 158.0, 152.1, 145.8, Int. J. Mol. Sci. 2011, 12  6111 
 
132.9, 132.8, 130.3, 130.2, 128.8, 128.1, 127.9, 125.1, 125.0, 123.9, 116.6, 116.4, 115.8; MS (ESI)   
m/z: 231.0 ([M − H]
–, 100); HRMS (ESI): Calcd. for C13H9F1O3 [M − H]
–: 231.0463; Found: 231.0463. 
Compounds 2c-4c were prepared in the similar manner as described for 1c. 
3-fluoro-3',4'-dihydroxyl  benzophenone  (2c):  White  powder,  Yield  48%,  mp  104–106  °C;   
1H NMR (DMSO-d6) δ: 7.44–7.59 (m, 4H, Ph-2,4,5,6-H), 7.27 (d, 1H, J =2.0 Hz, Ph-2’-H), 7.15 (dd, 
1H, J = 2.0, 8.0 Hz, Ph-6’-H), 6.89 (d, 1H, J = 8.4 Hz, Ph-5’-H), 5.00 (br, 2H, Ph-OH); 
13C NMR 
(DMSO-d6)  δ:  193.4,  163.4,  161.0,  151.5,  145.7,  141.8,  141.2,  141.1,  131.0,  130.9,  128.1,   
125.6, 124.1, 117.3, 115.7; MS (ESI) m/z: 231.0 ([M − H]
–, 100); HRMS (ESI): Calcd. for C13H9F1O3 
[M − H]
–: 231.0463; Found: 231.0463. 
4-fluoro-3',4'-dihydroxyl  benzophenone  (3c):  White  powder,  Yield  55%,  mp  155–157  °C;   
1H  NMR  DMSO-d6) δ:  7.73–7.76  (m,  2H,  Ph-2,6-H),  7.35–7.39 (m,  2H,  Ph-3,5-H),  7.24  (d,  1H,   
J = 2.0 Hz, Ph-2’-H), 7.11 (dd, 1H, J = 2.0, 8.0 Hz, Ph-6'-H), 6.87 (d, 1H, J = 8.0 Hz, Ph-5'-H),   
3.34 (br, 2H, Ph-OH); 
13C NMR (CD3OD) δ: 194.3, 164.0, 158.1, 146.0, 133.4, 133.3, 133.2, 125.2, 
123.1, 118.0, 116.4, 116.2, 115.8; MS (ESI) m/z: 231.0 ([M − H]
–, 100); HRMS (ESI): Calcd. for 
C13H9F1O3 [M − H]
–: 231.0463; Found: 231.0464. 
2-iodo-3',4'-dihydroxyl  benzophenone  (4c):  White  powder,  Yield  60%,  mp  186–188  °C; 
1H  NMR 
(DMSO-d6) δ: 7.89–7.95 (m, 1H, Ph-3-H), 7.46–7.54 (m, 1H, Ph-6-H), 7.16–7.31 (m, 2H, Ph-4,5-H), 
7.00 (dd, 1H, J = 1.6, 8.4 Hz, Ph-6’-H), 6.77 (s, 1H, Ph-2’-H), 6.41 (d, 1H, J = 8.4 Hz, Ph-5’-H); 
13C 
NMR (CD3OD) δ: 198.4, 153.2, 146.7, 146.6, 140.6, 131.9, 130.4, 129.0, 128.9, 126.2, 117.7, 116.0, 
92.8; MS (ESI) m/z: 339.0 ([M − H]
–, 100); HRMS (ESI): Calcd. for C13H9I1O3 [M − H]
–: 338.9524; 
Found: 338.9514. 
3.2.4. The Preparation of Compounds 1d–4d 
2-fluoro-3',4'-dihydroxyl diphenylmethane (1d): To a cooled (−78 °C) solution of compound 1b (400 
mg, 1.63 mmol) in dried CH2Cl2 (5 mL) was dropwisely added 5 mL BBr3 solution (BBr3/CH2Cl2, v/v, 
1/9). The mixture was warmed to room temperature, stirred for 15 min, and poured into ice-water (50 
mL).  The  organic  layer  was  separated.  The  water  layer  was  extracted  twice  with  ethyl  acetate   
(2  ×  10  mL).  The  combined  organics  were  washed  with  10  mL  water  and  dried  over  anhydrous 
Na2SO4,  then  concentrated  via  rotary  evaporation.  The  crude  product  was  purified  by  silica  gel 
chromatography  with  ethyl  acetate/petroleum  ether  (3/7,  containing  1  mL  acetic  acid  in  100  mL 
elution solvent) as eluent to afford compound 1d as pale yellow powder in 40% yield. mp 91–92 °C; 
1H NMR (DMSO-d6) δ: 8.80 (dd, 1H, J = 4.8, 41.6 Hz, Ph-6-H), 7.10–7.27 (m, 3H, Ph-3,4,5-H), 6.67 
(d, 1H, J = 8.0 Hz, Ph-6’-H), 6.59 (s, 1H, Ph-2’-H), 6.50 (d, 1H, J = 8.0 Hz, Ph-5'-H), 3.79 (s, 2H, 
CH2), 3.42 (br, 2H, Ph-OH); 
13C NMR (DMSO-d6) δ: 162.0, 159.5, 145.6, 144.1, 131.7, 131.6, 131.1, 
129.1, 128.9, 128.5, 128.4, 124.8, 124.7, 119.7, 116.4, 116.0, 115.7, 115.5, 33.9; MS (ESI) m/z: 217.0 
([M − H]
−, 100); HRMS (ESI): Calcd. for C13H11F1O2 [M − H]
−: 217.0670; Found: 217.0672. 
Compounds 2d–4d were prepared in the similar manner as described for 1d. 
3-fluoro-3',4'-dihydroxyl  diphenylmethane  (2d):  Pale  yellow  powder,  Yield  66%,  mp  66–68  °C;   
1H  NMR  (DMSO-d6)  δ:  7.28–7.34  (m,  1H,  Ph-5-H),  6.99–7.04  (m,  3H,  Ph-2,4,6-H),  6.68   Int. J. Mol. Sci. 2011, 12  6112 
 
(d, 1H, J = 8.0 Hz, Ph-5’-H), 6.60 (d, 1H, J = 2.0 Hz, Ph-2’-H), 6.51 (dd, 1H, J = 2.0, 8.0 HZ, Ph-6'-H), 
3.78 (s, 2H, CH2), 3.42 (br, 2H, Ph-OH); 
13C NMR (DMSO-d6) δ: 163.9, 161.5, 145.6, 145.5, 145.4, 
144.1, 131.9, 130.6, 130.5, 125.1, 119.9, 116.6, 116.0, 115.7, 115.5, 113.1, 112.9, 40.5; MS (ESI)   
m/z:  217.0  ([M  −  H]
−,  100);  HRMS  (ESI):  Calcd.  for  C13H11F1O2  [M  −  H]
−:  217.0670;   
Found: 217.0672. 
4-fluoro-3',4'-dihydroxyl  diphenylmethane  (3d):  White  powder,  Yield  59%,  mp  59–61  °C;   
1H NMR (DMSO-d6) δ: 7.32–7.86 (m, 2H, Ph-2,6-H), 6.95–7.23 (m, 2H, Ph-3,5-H), 6.66 (d, 1H,   
J = 8.0 Hz, Ph-5'-H), 6.55 (d, 1H, J = 2.0 Hz, Ph-2'-H), 6.45 (dd, 1H, J = 2.0, 8.0 Hz, Ph-6'-H),   
3.88 (s, 2H, CH2), 3.38 (br, 2H, Ph-OH); 
13C NMR (DMSO-d6) δ: 162.3, 159.9, 145.6, 143.9, 138.6, 
138.5, 132.5, 130.8, 130.7, 119.8, 116.5, 116.0, 115.5, 115.3, 40.0; MS (ESI) m/z: 217.0 ([M − H]
−, 
100); HRMS (ESI): Calcd. for C13H11F1O2 [M − H]
−: 217.0670; Found: 217.0672. 
2-iodo-3',4'-dihydroxyl diphenylmethane (4d): White powder, Yield 40%, mp 130–132 °C; 
1H NMR 
(DMSO-d6)  δ:  7.86  (dd,  1H,  J  =  1.2,  8.0  Hz,  Ph-3-H),  7.36  (m,  1H,  Ph-5-H),  7.23  (dd,  1H,   
J = 1.6, 7.6 Hz, Ph-6-H), 6.99 (m, 1H, Ph-4-H), 6.66 (d, 1H, J = 8.0 Hz, Ph-5’-H), 6.55 (d, 1H,   
J = 2.0 Hz, Ph-2'-H), 6.47 (dd, 1H, J = 2.0, 8.0 Hz, Ph-6'-H), 3.88 (s, 2H, CH2), 3.38 (br, 2H, Ph-OH); 
13C NMR (DMSO-d6) δ: 144.4, 139.6, 130.9, 130.8, 128.9, 128.7, 120.0, 116.5, 116.4, 116.0, 115.9, 
101.8,  45.3;  MS  (ESI)  m/z:  325.0  ([M  −  H]
−,  100);  HRMS  (ESI):  Calcd.  for  C13H11I1O2   
[M − H]
−: 324.9731; Found: 324.9726. 
3.3. Pharmacology 
After removal of the male mouse (SD) meninges, the brain was weighted and homogenized with a 
glass  homogenizer  in  four  volumes  of  cold  medium  (containing  20  mmol/L  Tris–HCl,  pH  7.5,   
0.25 mol/L sucrose, 2 mmol/L DDT, 2 mmol/L EDTA, 2 mmol/L Na3VO4, 1 mmol/L DMSF, 215 mg/L 
aprotinin, 1 mg/L PTIFtatin, 5 mg/L leupeptin) at high speed. The mixture was centrifuged for 10 min 
at 1000 × g at 4 °C; the supernatant was collected and re-centrifuged for 10 min at 10,000 × g at 4 °C 
to obtain the target supernatant. The target supernatant that contained cytoplasmic tyrosine kinase was 
collected, separately packed and stored at –70 °C.   
PTK activity was determined by the ELISA method. In brief, the concentrations of PTKs used to 
construct calibration curves were as follows: 600, 500, 341, 200 and 100 × 10
–7 U/mL for PTK. 100 μL 
of 20 mg/L PGT (Sigma Aldrich) in 20 mmol/L PBS solution was added to 96-well microtiter plates at 
37 °C overnight. After removing excess substrate solution, PBS–Tween 20 (PBST) was used to wash 
the wells one time, which were dried for 2 h at 37 °C and kept at 4 °C. Subsequently, 50 μL of the 
above  PTK  extraction  (50  mmol/L  HEPES,  pH  7.4,  20  mmol/L  MgCl2,  0.1  mmol/L  MnCl2,   
0.2 mmol/L Na3VO4, 0.6 mmol/L ATP) was added to the 96-well plates. Then, a certain concentration 
of the tested compounds (10 μL) and tyrosine kinase tissue extract solution were incubated at 37 °C for 
1 h. The plate was washed three times with PBST at the end of the treatment, and 100 μL of the diluted 
horseradish-peroxidase-labeled  mouse  anti-phosphotyrosine  monoclonal  antibody  IgG2bk  (Sigma 
Aldrich) was added to each well, and incubated at 37 °C for 30 min. After removal of the antibody 
complex,  and  then  washing  three  times  with  PBST,  100  μL  freshly  prepared  TMB  horseradish 
peroxidase color development solution (Beijing 4A Biotech Co., Ltd, China) was added and protected Int. J. Mol. Sci. 2011, 12  6113 
 
from light for 10 min. The reaction was terminated by addition of 100 μL/well 1 N sulfuric acid. 
Absorbance was measured at 450 nm in a microplate reader (SpectraMax M5) [4]. 
4. Conclusions 
In  this  study,  we  prepared  a  series  of  new  benzophenone  and  diphenylmethane  halophenol 
derivatives and investigated the influence of the linker, substituted groups, number and positions of 
halogen atoms on PTK inhibitory activities. 
All of the chlorophenols exhibited strong activities, and the substituted position of the chloro atom 
also  markedly  affected  the  activity.  Unfortunately,  all  of  the  fluoro-  and  iodo-  functionalized 
compounds were inactive. Our findings confirmed that the hydroxyls and halogens (chloro or bromo) 
seem to be essential to the activity, and the chloro atom and methylene group play a crucial role in the 
activity. Hence, these compounds with high activities represent a new paradigm for halophenols and 
appear to offer great potential as new PTK inhibitors. The results also gave a relatively full recognition 
of the SARs, and provided a foundation for further structural optimization of the halophenols in the 
search for suitable clinical candidates. 
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